Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective
dc.contributor.author | Sharma, Prateek | en_US |
dc.contributor.author | Chey, William D. | en_US |
dc.contributor.author | Hunt, Richard | en_US |
dc.contributor.author | Laine, Loren | en_US |
dc.contributor.author | Malfertheiner, Peter | en_US |
dc.contributor.author | Wani, Sachin | en_US |
dc.date.accessioned | 2010-06-01T18:31:45Z | |
dc.date.available | 2010-06-01T18:31:45Z | |
dc.date.issued | 2009-08 | en_US |
dc.identifier.citation | Sharma, Prateek; Chey, William; Hunt, Richard; Laine, Loren; Malfertheiner, Peter; Wani, Sachin (2009). "Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective." Diseases of the Esophagus 22(5): 461-466. <http://hdl.handle.net/2027.42/71735> | en_US |
dc.identifier.issn | 1120-8694 | en_US |
dc.identifier.issn | 1442-2050 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/71735 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19191851&dopt=citation | en_US |
dc.description.abstract | Gastroesophageal reflux disease (GERD) is an extremely common chronic disorder associated with impaired quality of life and huge economic burden. Recently, an International Consensus Group developed a global definition of GERD (The Montreal Definition): a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications. The traditional endoscopy-based classification of GERD patients into one of three groups – non-erosive reflux disease, erosive esophagitis, and Barrett's esophagus – is fraught with several limitations. Due to the lack of a gold standard, GERD is a symptom-based diagnosis, and hence symptom evaluation will remain the primary means by which treatment decisions are made for patients with suspected GERD. We propose that patients reporting the predominant GERD-like symptoms (GERS) in the primary care setting be classified based upon their response to an empiric trial of acid suppressive therapy: complete response to acid suppressive therapy, partial response to acid suppressive therapy, and no response to acid suppressive therapy. Given the limitations of objective medical testing, implementation of our proposed new symptom-based classification of patients with GERS would guide primary care physicians on when to refer patients to a gastroenterologist, which in turn could help in better resource utilization. Validation of this proposed classification by well-designed prospective multicenter studies is awaited. | en_US |
dc.format.extent | 117854 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.rights | © 2009 International Society for Diseases of the Esophagus | en_US |
dc.subject.other | Barrett's Esophagus | en_US |
dc.subject.other | Endoscopy | en_US |
dc.subject.other | Erosive Esophagitis | en_US |
dc.subject.other | Gastroesophageal Reflux Disease | en_US |
dc.subject.other | Non-erosive Reflux Disease | en_US |
dc.title | Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan; | en_US |
dc.contributor.affiliationother | Division of Gastroenterology and Hepatology, University of Kansas School of Medicine and Veterans Affairs Medical Center, Kansas City, Missouri; | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, McMaster University Medical Center, Hamilton, Ontario, Canada; | en_US |
dc.contributor.affiliationother | GI Liver Division, USC School of Medicine, Los Angeles, California, USA; and | en_US |
dc.contributor.affiliationother | Otto-von Guericke University of Magdeburg, Magdeburg, Germany | en_US |
dc.identifier.pmid | 19191851 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/71735/1/j.1442-2050.2008.00934.x.pdf | |
dc.identifier.doi | 10.1111/j.1442-2050.2008.00934.x | en_US |
dc.identifier.source | Diseases of the Esophagus | en_US |
dc.identifier.citedreference | Bardhan K D, Stanghellini V, Armstrong D, BerghÖfer P, Gatz G, MÖnnikes H. Evaluation of GERD symptoms during therapy. Part I: development of the new GERD questionnaire ReQuest. Digestion 2004; 69: 229 – 37. | en_US |
dc.identifier.citedreference | Kulig M, Nocon M, Vieth M et al. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the proGERD study. J Clin Epidemiol 2004; 57 ( 6 ): 580 – 9. | en_US |
dc.identifier.citedreference | Shaheen N J, Hansen R A, Morgan D R et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128 – 38. | en_US |
dc.identifier.citedreference | Liu J Y, Woloshin S, Laycock W S, Rothstein R I, Finlayson S R, Schwartz L M. Symptoms and treatment burden of gastroesophageal reflux disease: validating the GERD assessment scales. Arch Intern Med 2004; 164: 2058 – 64. | en_US |
dc.identifier.citedreference | Heading R C. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol Suppl 1999; 231: 3 – 8. | en_US |
dc.identifier.citedreference | Dent J, El-Serag H B, Wallander M A, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710 – 7. | en_US |
dc.identifier.citedreference | Talley N J, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy negative heartburn: reliability and severity of disease-specific instruments. Am J Gastroenterol 2001; 96: 1998 – 2004. | en_US |
dc.identifier.citedreference | McDougall N I, Johnston B T, Kee F, Collins J S, McFarland R J, Love A H. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patients symptomatology and quality of life. Gut 1996; 38: 481 – 6. | en_US |
dc.identifier.citedreference | Dent J. Definitions of reflux disease and its separation from dyspepsia. Gut 2002; 50 ( Suppl 4 ): iv17 – 20. | en_US |
dc.identifier.citedreference | Dent J, Brun J, Fendrick A M et al. An evidence-based appraisal of reflux disease management–the Genval Workshop Report. Gut 1999; 44 ( Suppl 2 ): S1 – 16. | en_US |
dc.identifier.citedreference | Vakil N, van Zanten S V, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900 – 20. | en_US |
dc.identifier.citedreference | Falk G W, Fennerty B F, Rothstein R I. AGA institute technical review on the use of endoscopic therapy for gastroesophageal reflux disease. Gastroenterology 2006; 131 ( 4 ): 1315 – 36. | en_US |
dc.identifier.citedreference | Locke G R III, Talley N J, Fett S L, Zinsmeister A R, Melton L J III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112 ( 5 ): 1448 – 56. | en_US |
dc.identifier.citedreference | Fass R, Ofman J J. Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002; 97: 1901 – 9. | en_US |
dc.identifier.citedreference | Kahrilas P J. Diagnosis of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98: S15 – 23. | en_US |
dc.identifier.citedreference | Ronkainen J, Aro P, Storskrubb T et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40: 275 – 85. | en_US |
dc.identifier.citedreference | Carlsson R, Dent J, Watts R et al. Gastro-oesophageal reflux disease (GORD) in primary care–an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119 – 24. | en_US |
dc.identifier.citedreference | Quigley E M. Non-erosive reflux disease: part of the spectrum of gastro-oesophageal reflux disease, a component of functional dyspepsia, or both? Eur J Gastroenterol Hepatol 2001; 13 ( Suppl 1 ): S13 – 8. | en_US |
dc.identifier.citedreference | Quigley E M. The spectrum of GERD: a new perspective. Drugs Today 2005; 41 ( Suppl B ): 3 – 6. | en_US |
dc.identifier.citedreference | Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005; 22: 79 – 94. | en_US |
dc.identifier.citedreference | Quigley E M. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities? Best Pract Res Clin Gastroenterol 2004; 18 ( 4 ): 695 – 706. | en_US |
dc.identifier.citedreference | Shaw M. Diagnostic utility of reflux disease symptoms. Gut 2004; 53 ( Suppl IV ): iv25 – 27. | en_US |
dc.identifier.citedreference | Monnikes H, Bardhan K D, Stanghellini V, BerghÖfer P, Bethke T D, Armstrong D. Evaluation of GERD symptoms during therapy. Part II: psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD. Digestion 2004; 69: 238 – 44. | en_US |
dc.identifier.citedreference | Van Pinzteren B, Numans M, Bonis P, Lau J. Short-term treatment with proton pump inhibitors, H2 receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2001: CD002095. | en_US |
dc.identifier.citedreference | 25 National Institute for Clinical Excellence. Dyspepsia: management of dyspepsia in adults in primary care. Clinical guideline 17, 2004 Aug. [Cited September 17, 2008] Available from URL: http://www.nice.org.uk/CG017NICEguideline | en_US |
dc.identifier.citedreference | Vakil N. How valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005; 22 ( Suppl 1 ): 64 – 9. | en_US |
dc.identifier.citedreference | Bardhan K D, Muller-Lissner S, Bigard M A et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318: 502 – 7. | en_US |
dc.identifier.citedreference | Lind T, Havelund T, Carlsson R et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974 – 9. | en_US |
dc.identifier.citedreference | Dean B B, Gano A D, Knight K, Ofman J J, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656 – 64. | en_US |
dc.identifier.citedreference | Numans M E, Lau J, de Wit N J, Bonis P A. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140: 518 – 27. | en_US |
dc.identifier.citedreference | Nojkov B, Chey W D, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Gastroenterology 2005; 128: AB416. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.